Published in Curr Opin Oncol on July 01, 2015
Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine? EBioMedicine (2016) 0.75
Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review. Oncologist (2016) 0.75
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res (2012) 2.46
Molecular pathogenesis of osteosarcoma. DNA Cell Biol (2007) 2.31
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet (2012) 1.84
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 1.83
A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol (2012) 1.80
RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev (2007) 1.57
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res (2013) 1.54
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics (2014) 1.53
Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets. Bioessays (2014) 1.40
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat (2011) 1.38
Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer (2008) 1.37
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res (2006) 1.27
Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res (2010) 1.26
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. Proc Natl Acad Sci U S A (2008) 1.22
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A (2013) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) (2011) 1.21
Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci (2006) 1.15
Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem (2012) 1.13
A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. BMC Cancer (2011) 1.12
HES1 cooperates with pRb to activate RUNX2-dependent transcription. J Bone Miner Res (2006) 1.12
PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer (2006) 1.11
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol (2011) 1.07
Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res (2008) 1.05
The relationship between unmet needs and distress amongst young people with cancer. Support Care Cancer (2011) 1.04
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res (2005) 1.02
Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity. J Neurochem (2012) 1.01
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One (2010) 1.01
Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. Cancer Res (2009) 0.99
The Angelina Jolie effect. Med J Aust (2013) 0.99
Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer (2010) 0.96
Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem (2013) 0.96
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer (2009) 0.94
Next-generation sequence analysis of cancer xenograft models. PLoS One (2013) 0.94
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin Sarcoma Res (2012) 0.94
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J Clin Invest (2013) 0.92
Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn (2011) 0.91
The tubal hypothesis of ovarian cancer: caution needed. Lancet Oncol (2011) 0.90
Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity. Ann N Y Acad Sci (2008) 0.87
Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. PLoS One (2013) 0.86
High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One (2013) 0.85
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer (2011) 0.85
The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia Pac J Clin Oncol (2011) 0.85
Soman increases neuronal COX-2 levels: possible link between seizures and protracted neuronal damage. Neurotoxicology (2010) 0.84
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. J Clin Oncol (2011) 0.84
Cancer-associated neochromosomes: a novel mechanism of oncogenesis. Bioessays (2009) 0.83
Triple-negative breast cancer: making the most of a misnomer. Asia Pac J Clin Oncol (2012) 0.83
Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther (2012) 0.83
The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study. Genet Med (2013) 0.82
The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. Fam Cancer (2013) 0.82
Nucleus accumbens invulnerability to methamphetamine neurotoxicity. ILAR J (2011) 0.82
Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma (2010) 0.82
Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing. Oncol Nurs Forum (2012) 0.82
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer (2011) 0.81
The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. BMC Cancer (2013) 0.81
Health professionals' evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer. Fam Cancer (2015) 0.80
A role for alphaV integrin subunit in TGF-beta-stimulated osteoclastogenesis. Biochem Biophys Res Commun (2003) 0.80
Novel approaches to treatment of leiomyosarcomas. Curr Oncol Rep (2011) 0.80
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res (2013) 0.80
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett (2006) 0.80
Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review. Clin Sarcoma Res (2013) 0.80
Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 0.79
Regulation of fetal versus embryonic gamma globin genes: appropriate developmental stage expression patterns in the presence of HS2 of the locus control region. Blood (2002) 0.79
Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol (2012) 0.79
The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research. Clin Sarcoma Res (2013) 0.79
Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. Fam Cancer (2015) 0.79
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep (2013) 0.78
The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. Expert Rev Mol Diagn (2008) 0.78
Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. Oncoimmunology (2012) 0.78
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma (2013) 0.78
Other targetable sarcomas. Semin Oncol (2009) 0.78
A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Arch (2012) 0.78
Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale. Cancer Epidemiol Biomarkers Prev (2006) 0.77
kConFab: a familial breast cancer consortium facilitating research and translational oncology. J Natl Cancer Inst Monogr (2011) 0.76
Ductal approaches to assessment and management of women at high risk for developing breast cancer. Breast Cancer Res (2004) 0.76
Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer. ANZ J Surg (2011) 0.76
No evidence for PALB2 methylation in high-grade serous ovarian cancer. J Ovarian Res (2013) 0.76
Use of ketamine for ischemic pain in end-stage renal failure. J Pain Symptom Manage (2008) 0.76
The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. Fam Cancer (2012) 0.75
Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics (2013) 0.75
Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.75
Analysis of KLLN as a high-penetrance breast cancer predisposition gene. Breast Cancer Res Treat (2012) 0.75
Molecular profiling of non-small cell lung cancer: of what value in clinical practice? Heart Lung Circ (2008) 0.75
The hard and soft sides of cancer programming. Bioessays (2010) 0.75
Tobacco smoke modulates ozone-induced toxicity in rat lungs and central nervous system. Inhal Toxicol (2013) 0.75